It is a simple bet for TA guys. ALL TA studies are indicating BUY SIGNALS. This with the fact that it trades above $6 EVERY YEAR regardless of most anything, and you have to ask why it would not this year as well. After all, this company has an approved drug now, with vast potential for huge expanded use, and many other things on the go. Cash as well. Not one chance of this folding, as is the case with so many biotech situations. Is this the run to above $6? Take a look at the chart and come to your own conclusions.
DC - I think you misread the original post - bit of a double negative there, which can be using. I think the original post was stating that EXEL has been above $6 at least once, every year, for the last ten years.